Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. …
Ligand Pharmaceuticals Inc. (LGND) reported second quarter EPS of $0.67 after the bell Monday, up from $0.35 in the prior year period. Ligand Pharmaceuticals gapped open higher Tuesday and spiked to the upside in early trade. The …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LGND at https://www.zacks.com/ap/LGND Keywords: Ligand …
Ligand Pharmaceuticals Incorporated LGND is scheduled to report second-quarter 2016 results ... Ligand is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks …
We cover insider selling every week at 24/7 Wall St., and we like to remind our readers that just because an individual or 10% institutional owner is selling stock, that is no cause ... Pharmaceutical Inc. (NASDAQ: LGND), Robert Half Inc. …
The MLA Amendment also amended the upfront payments to the Company of Viking capital stock. If Viking completes …
This method discovered several great candidates for momentum-oriented investors, but today let's focus in on Ligand Pharmaceuticals Incorporated LGND as this stock is looking especially impressive right now. And while there are …
NASDAQ5mon
Ligand Pharmaceuticals Incorporated LGND is scheduled to report second-quarter 2016 results on Aug 4 before the market opens. In the last reported quarter, Ligand had posted a positive earnings surprise of 67.39%. Let’s see how things are …